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The ongoing revolution in molecular medicine can be
divided into three phases. The first phase is gene discov-
ery, in which the tools of molecular biology are applied to
identify and sequence previously unknown genes. Identifi-
cation of most of the expressed human genes will be
accomplished before 2005. The second phase is molecu-
lar fingerprinting, which correlates the genomic state, the
complementary DNA expression pattern, and the protein
repertoire with the functional status of the cells or tissue.
The promise of this phase is that expression profiles can
uncover clues to functionally important molecules, and will
generate information to tailor a treatment to the individual
patient. The third phase is the synthesis of proteomic infor-
mation into functional pathways and circuits in cells and
tissues. This must take into account the dynamic state of
protein post-translational modifications and protein–protein
or protein–DNA interactions. Through an integrated
genomic/proteomic analysis, the ultimate outcome will be
an actual functional understanding of the molecular events
that underlie normal development and disease pathophysi-
ology. This higher level of functional understanding will be
the basis for true rational therapeutic design.
Progress in these three phases of molecular medicine is
largely driven by new technologies. The development of
polymerase chain reaction, high throughput sequencing,
and bioinformatics has been a driving force in the first
phase. In the second phase, microhybridization arrays
applied to genetic analysis and gene expression [1] is a
powerful new tool that has entered the commercial sector,
and is becoming widely available to researchers. As more
genes are identified, it is likely that specialized arrays will
be offered that are specific for a tissue type (eg mammary
gland chip), physiologic process (eg apoptosis chip,
angiogenesis chip, invasion chip) or class of genes (eg
suppressor gene chip, oncogene chip).
Whereas DNA is an information archive, proteins do all the
work of the cell. The existence of a given DNA sequence
does not guarantee the synthesis of a corresponding
protein [2,3]. The DNA sequence is also not sufficient to
describe protein structure, function, and cellular location.
This is because protein complexity and versatility stems
from context-dependent post-translational processes such
as phosphorylation, sulfation, and glycosylation. Moreover,
the DNA code does not provide information about how
proteins link together into networks and functional
machines in the cell. In fact, the activation of a protein
signal pathway causing a cell to migrate, die, or initiate
division can immediately take place before any changes
occur in DNA/RNA gene expression. Consequently, the
technology to drive the molecular medicine revolution into
the third phase is emerging from protein analytic methods.
The term ‘proteome’, which denotes all the proteins
expressed by a genome, was first coined in late 1994 at the
Siena two-dimensional gel electrophoresis meeting [4]. Pro-
teomics is proclaimed as the next step after genomics. A
goal of investigators in this exciting field is to assemble a
complete library of all of the proteins. Only a small percent-
age of the proteome has been cataloged to date [2,3].
Because ‘polymerase chain reaction for proteins’ does not
exist, sequencing the order of 20 possible amino acids in a
given protein remains relatively slow and labor intensive,
compared with nucleotide sequencing. Although a number
of new technologies are being introduced for high through-
put protein characterization and discovery [3,5], the main-
stay of protein identification continues to be
two-dimensional gel electrophoresis. Two-dimensional elec-
trophoresis can separate proteins by molecular weight in
one dimension and charge in the second dimension. When
a mixture of proteins is applied to the two-dimensional gel,
individual proteins in the mixture are separated out into sig-
nature locations on the display, depending on their individ-
ual size and charge. Each signature is a ‘spot’ on the gel,
which can constitute a unique single protein species. The
protein spot can be procured from the gel and a partial
amino acid sequence can be read. In this manner known
proteins can be monitored for changes in abundance under
treatment or new proteins can be identified. An experimental
two-dimensional gel image can be captured and overlayed
digitally with known archived two-dimensional gels. In thisBreast Cancer Research    Vol 2 No 1 Liotta
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way it is possible to immediately highlight proteins that are
differentially abundant in one state versus another (eg tumor
versus normal, or before and after hormone treatment).
Two-dimensional gels have traditionally required large
amounts of protein starting material, equivalent to millions of
cells. Thus, their application has been limited to cultured
cells or ground-up heterogeneous tissue. Not unexpectedly,
this approach does not provide an accurate picture of the
proteins that are in use by cells in real tissue. Tissues are
complicated structures composed of hundreds of interact-
ing cell populations in specialized spatial configurations.
The fluctuating proteins expressed by cells in tissues may
bear little resemblance to the proteins made by cultured
cells that are torn from their tissue context and reacting to a
new culture environment. Proteins extracted from ground-up
tissue will represent an averaging-out of proteins from all of
the heterogeneous tissue subpopulations. For example, in
the case of breast tissue the glandular epithelium consti-
tutes a small proportion of the tissue; the vast majority is
stroma and adipose. Thus, it has previously been impossible
to obtain a clear snapshot of gene or protein expression
within normal or diseased tissue cell subpopulations.
To address the tissue-context problem, new technology is
again coming to the rescue; creating ‘tissue proteomics’
as an exciting expanding discipline. Two major technologic
approaches have been successfully used to sample
macromolecules directly from subpopulations of human
tissue cells. The first technology is laser capture microdis-
section. This is a technology for procuring specific tissue
cell subpopulations under direct microscopic visualization
of a standard stained frozen or fixed tissue section on a
glass microscope slide. This technology was invented at
the US National Institutes of Health and is commercially
available through Arcturus Engineering (Mountain View,
CA, USA; www.arctur.com). Tissue cells procured by
laser capture microdissection have been used for highly
sensitive and reproducible proteomic analysis using two-
dimensional gels and other analytic methods [6–8].
A second major approach to isolate tissue cell subpopula-
tions is affinity cell sorting of dissaggregated cells from
pieces of fresh tissue. A highly notable application of this
technology in the field of breast physiology was recently
reported [9] in a study resulting from a collaboration
between Oxford Glycosciences (Oxford, UK) and the
Ludwig Institute (London, UK). In that study the investiga-
tors separated and purified normal human breast luminal
and myoepithelial tissue from reduction mammoplasty
specimens using double antibody magnetic affinity cell
sorting and Dynabead magnetic sedimentation (Dynal Inc,
UK). After using enzymatic treatments and various incuba-
tion, separation, and washing steps, the investigators
obtained purified luminal and myoepithelial cells in yields
of 5×106–2×10 7. Proteins from these cell populations
were then analyzed using two-dimensional gels. A master
image for each cell type comprising a total of 1738 dis-
tinct proteins was derived. The investigators found 170
protein spots that were elevated twofold or more between
the two populations. Of these, 51 were further character-
ized by tandem mass spectroscopy. The proteins prefer-
ential to the myoepithelial cells contained muscle-specific
enzymes and structural proteins consistent with the con-
tractile muscle-related derivation of these cell types.
Myoepithelial cells are a fascinating component of breast
tissue. They are thought to play important roles in duct and
lobule growth, matrix architecture, and remodeling after lac-
tation and involution. A pathologic hallmark of early cancer
progression from carcinoma in situ to invasive cancer is the
loss or redistribution of myoepithelial cells. The conspicuous
absence of myoepithelial cells in breast cancer progression
could mean that these cells produce suppressor proteins
that normally keep the malignant cells in check. Thus, one or
more of the proteins identified in the study by Page et al
[10] could be candidate cancer prevention molecules. The
authors of that study concluded that ‘These observations
demonstrate that proteomics has the refinement and sensi-
tivity to find proteins that are either uniquely or differentially
expressed between different cell types, the consequences
of which could enable new strategies for drug discovery.’
References
1. DeRisi J, Penland L, Brown P, et al: Use of a cDNA microarray to
analyse gene expression patterns in human cancer. Nature Genet
1996, 14:457–460.
2. Humphery-Smith I, Cordwell SJ, Blackstock WP: Proteome research:
complementarity and limitations with respect to the RNA and DNA
worlds. Electrophoresis 1997, 18:1217–1242.
3. Hancock W, Apffel A, Chakel J, et al: Integrated genomic/proteomic
analysis. Anal Chem 1999, 71:743–748.
4. Williams K, Hochstrasser D: In: Proteome Research: New Frontiers in
Functional Genomics. Edited by Wilkins M, Williams K, Appel R,
Hochstrasser D. Berlin: Springer Press, 1997:1–12.
5. Gygi SP Rist B, Gerber S, et al: Quantitative analysis of complex
protein mixtures using isotope-coded affinity tags. Nature Biotech-
nol 1999, 17:994–999.
6. Emmert-Buck M, Bonner R, Smith P, et al: Laser capture microdis-
section. Science 1996, 274:998–1001.
7. Banks RE, Dunn M, Forbes M, et al: The potential use of laser
capture microdissection to selectively obtain distinct populations
of cells for proteomic analysis. Electrophoresis 1999, 20:689–700.
8. Emmert-Buck M, Paweletz C, Gillespie J, et al: An approach to pro-
teomic analysis of human tumors. Mol Carcinogen (in press).
9. Paweletz C, Gillespie J, Ornstein D: Rapid protein display profiling
of cancer progression directly from human tissue using a protein
biochip. Drug Dev Res 2000 (in press).
10. Page MJ, Arness B, Townsend R, et al: Proteomic definition of
normal human luminal and myoepithelial breast cells purified
from reduction mammoplasties. Proc Natl Acad Sci USA 1999, 96:
12589–12594.
Author’s affiliation: Lance A Liotta (Laboratory of Pathology, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland,
USA) and Emanuel F Petricoin (Division of Therapeutic Proteins,
CBER/Food and Drug Administration, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland, USA)
Correspondence: Lance A Liotta, MD, PhD, Laboratory of Pathology,
National Cancer Institute, National Institutes of Health, Bethesda, MA,
USA. E-mail: lance@helix.nih.gov